Trial Profile
Effect of Fluvoxamine Augmentation on Cognitive Function , Aggressive Behavior , Clinical Symptoms and mRNA and Protein Expression in Human Peripheral Mononuclear Blood Cells (PMC) in Medicated Schizophrenia Patients
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Fluvoxamine (Primary) ; Antipsychotics
- Indications Schizophrenia
- Focus Pharmacogenomic; Therapeutic Use
- 30 Apr 2013 New trial record